Table 1 Demographic information of patients with Sjögren’s disease and healthy controls.

From: Salivary kynurenine pathway metabolites as potential non-invasive markers of glandular dysfunction in Sjögren’s disease

 

SjD, n = 39

HCs, n = 32

Age at baseline, years

54 (47–61)

52 (42–61)

Age at diagnosis, years

47 (38–58)

 

Sex, female

38 (97.4)

32 (93.8)

Disease duration, months

6 (0–36)

 

Dry eye

39 (100)

 

Dry mouth

37 (94.9)

 

UWSFR ≤ 0.1 ml/min

25 (64.1)

 

Focus score

3 (2–8)

 

ESSDAI total score

4 (0–7)

 

ESSPRI overall score

4.7 (4.0–6.8)

 

Any extraglandular manifestations

26 (66.7)

 

Pilocarpine

33 (84.6)

 

Corticosteroid

19 (48.7)

 

Hydroxychloroquine

20 (51.3)

 

Anti-Ro positivity

33 (84.6)

 

Anti-La positivity

19 (48.7)

 

Rheumatoid factor positivity

25 (64.1)

 

Low C3

8 (20.5)

 

Low C4

4 (10.3)

 

Hypergammaglobulinemia

9 (23.1)

 
  1. All data are expressed as number (%) or median (interquartile range). SjD: Sjögren’s disease, HCs: healthy controls, UWSFR: unstimulated whole salivary flow rate, ESSDAI: EULAR Sjogren’s syndrome disease activity index, ESSPRI: EULAR Sjogren’s syndrome patient-reported index.
Back to article page